tiprankstipranks
Pressure Biosciences Inc (PBIO)
:PBIO
US Market

Pressure Biosciences (PBIO) AI Stock Analysis

Compare
62 Followers

Top Page

PB

Pressure Biosciences

(OTC:PBIO)

32Underperform
Pressure Biosciences' score reflects significant financial instability with high leverage and negative cash flows. The absence of positive technical indicators and valuation metrics further weighs on the stock. The lack of guidance or sentiment from the earnings call adds uncertainty, limiting any positive outlook in the near term.

Pressure Biosciences (PBIO) vs. S&P 500 (SPY)

Pressure Biosciences Business Overview & Revenue Model

Company DescriptionPressure BioSciences, Inc. (PBIO) is a life sciences company focused on developing and commercializing innovative technologies and products for the global healthcare, biotechnology, pharmaceutical, and food industries. The company specializes in high-pressure-based scientific instruments and associated consumables, which are used for various applications, including biomarker discovery, drug design, food safety, and pathogen inactivation. PBIO's core technology platform, Pressure Cycling Technology (PCT), enables the manipulation of biomolecules and cellular structures in a unique manner, enhancing the quality and efficiency of scientific research and development.
How the Company Makes MoneyPressure BioSciences generates revenue primarily through the sale of its proprietary high-pressure instruments and consumable products. The company markets its Pressure Cycling Technology (PCT) systems to research institutions, biotechnology and pharmaceutical companies, and government entities. Revenue streams include direct sales of instruments, recurring sales of consumables required for ongoing use of the systems, and service contracts for maintenance and support of the equipment. Additionally, PBIO may engage in collaborative partnerships and licensing agreements that provide funding and the potential for milestone payments and royalties. The company's growth is supported by its focus on expanding applications for its technology across various sectors, thereby increasing its customer base and market penetration.

Pressure Biosciences Financial Statement Overview

Summary
Pressure Biosciences is facing significant financial challenges with negative net income, high debt levels, negative cash flows, and negative stockholders' equity, indicating financial instability and ongoing profitability issues.
Income Statement
30
Negative
Pressure Biosciences has shown some revenue growth from 2022 to 2023, but consistently negative net income and EBIT margins indicate ongoing profitability challenges. The net profit margin remains deeply negative, reflecting significant expenses relative to revenue.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity, indicating liabilities exceed assets, a concerning financial position. The high debt levels relative to equity suggest financial instability and potential difficulty in meeting long-term obligations.
Cash Flow
25
Negative
Operating cash flow is negative and free cash flow has not shown improvement, indicating cash generation issues. The company relies heavily on financing activities to support operations, which may not be sustainable long-term.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.50M1.98M1.73M2.00M1.22M1.81M
Gross Profit
421.66M799.56K-284.66K1.06M637.74K612.93K
EBIT
-8.61M-9.50M-4.90M-4.19M-4.59M-5.81M
EBITDA
-10.83M-9.39M-5.40M-5.53M-7.46M-6.41M
Net Income Common Stockholders
-31.36M-29.31M-16.82M-34.60M-24.35M-11.66M
Balance SheetCash, Cash Equivalents and Short-Term Investments
81.28K81.28K3.87K132.31K18.54K29.63K
Total Assets
1.05M1.05M2.01M2.83M2.30M1.82M
Total Debt
23.89M22.89M20.53M14.64M9.60M7.96M
Net Debt
23.80M22.80M20.53M14.51M9.58M7.93M
Total Liabilities
33.80M33.80M34.70M25.04M19.22M13.87M
Stockholders Equity
-32.75M-32.75M-32.69M-22.21M-16.92M-12.06M
Cash FlowFree Cash Flow
-2.57B-3.19M-4.50M-4.99M-4.88M-6.35M
Operating Cash Flow
-2.57B-3.19M-4.48M-4.87M-4.88M-6.33M
Investing Cash Flow
-7.49M-7.50K-20.75K-122.94K-796.66K-23.38K
Financing Cash Flow
2.50B3.27M4.37M5.11M5.67M6.28M

Pressure Biosciences Risk Analysis

Pressure Biosciences disclosed 40 risk factors in its most recent earnings report. Pressure Biosciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pressure Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$9.83B60.867.82%0.53%4.46%-29.62%
TMTMO
70
Outperform
$196.95B30.7713.15%0.31%0.05%6.87%
70
Outperform
$1.17B27.8425.01%8.52%-32.91%
BIBIO
49
Neutral
$7.14B-24.09%-3.92%-202.80%
49
Neutral
$6.87B0.03-54.93%2.50%24.65%-2.90%
46
Neutral
$2.44B-50.74%-7.03%-20233.78%
32
Underperform
$520.28K89.50%-20.28%13.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PBIO
Pressure Biosciences
0.01
-0.16
-94.12%
BIO
Bio-Rad Laboratories
254.45
-78.98
-23.69%
QDEL
QuidelOrtho
36.12
-12.88
-26.29%
TECH
Bio-Techne
62.16
-9.41
-13.15%
TMO
Thermo Fisher
522.05
-56.32
-9.74%
MDXG
MiMedx Group
7.92
0.04
0.51%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.